Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
US clinical stage developer Immunitas Therapeutics today announced the appointment of Annalisa D’Andrea as its chief scientific officer (CSO). 18 January 2024
With the aim of boosting is leadership team, clinical-stage biotech Zura Bio today announced the appointments of Robert Lisicki as president and chief operating officer, and Kiran Nistala as executive vice president development and chief medical officer, to the executive leadership team. 17 January 2024
Shares of US clinical-stage biotech Aclaris Therapeutics shot up as much as 40% to $1.21 in early trading today, after it announced leadership changes and that it is undertaking a strategic review of its business. 16 January 2024
New York, USA-based rare neurological disease drug developer Neurogene has announced the appointment of Julie Jordan as its chief medical officer (CMO). 16 January 2024
California, USA-based biotech start-up TORL BioTherapeutics has appointed of Mark Alles, currently executive chairman, to the additional post of chief executive (CEO). 12 January 2024
Rob Scott has been appointed chief medical officer (CMO) of Abionyx Pharma, a French biotech focused on the discovery and development of innovative therapies based on the world's only recombinant apoA-I. 10 January 2024
Paris, France-based cardiology specialist Corteria Pharmaceuticals has announced the appointment of Dr Mark Pruzanski, as chairman of its board of directors. 6 January 2024
Boston, USA-based biotech start-up Kojin Therapeutics has announced the appointment of Harvey Berger as its new chairman, president and chief executive (CEO). 5 January 2024
French immuno-oncology company Innate Pharma today announced that it has strengthened its leadership and corporate governance with the appointment of two new executive board members. 4 January 2024
UK-based Arecor Therapeutics has announced the appointment of Dr Helen Parris as senior vice president, commercial and general manager of Tetris Pharma. 3 January 2024
Cambridge, USA-based mRNA cell engineering focused biotech Eterna Therapeutics has appointed Sanjeev Luther as president and chief executive and a member of the company's board of directors, effective January 1, 2024. 21 December 2023
Avacta Group, a UK life sciences company developing innovative, targeted oncology drugs and diagnostics, has appointed Simon Bennett as chief business officer of the therapeutics division. 19 December 2023
Vicore Pharma, a Swedish pharma company seeking to unlock the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), has announced that Bertil Lindmark will join as chief medical officer. 18 December 2023